AstraZeneca’s Tagrisso divides on immediate adoption in adjuvant non-small cell lung cancer

nsclc
Tagrisso’s improved efficacy and safety profile in general versus the older EGFR TKIs and the DFS data was adequate to make treatment choices. Credit: Shutterstock.